/RTGN

RTGN Stock - RetinalGenix Technologies Inc.

Q: What is the analyst price target for RTGN?

Analyst price target information is not currently available for RTGN.

Q: What is RTGN's market cap?

Market capitalization information is not currently available for RTGN.

Healthcare|Medical - Devices|OTC

$3.20+0.00%

+$0.00 (+0.00%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $3.52

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for RTGN

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-3.96

52W High$6.36

52W Low$0.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	$-954	$-100	$-51	N/A	N/A
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-4,316,987	$-2,087,049	$-1,875,961	$-2,176,675	$-2,077,993
Net Income	$-4,320,827	$-2,090,889	$-3,913,990	$-2,181,913	$-2,077,993
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-0.24	$-0.12	$-0.25	$-0.15	$-0.05

Company Overview

RetinalGeniX Technologies, Inc., an ophthalmic research and development company, focuses on developing technologies to screen, monitor, diagnose, and treat ocular, optical, and sight-threatening disorders. Its products include the RetinalGeniX Imaging System, a diabetic non-mydriatic mass retinal imaging and screening device; and RetinalCam, a real-time in-home retinal monitoring, imaging, and physician alert system. The company was incorporated in 2017 and is headquartered in Petaluma, California. RetinalGenix Technologies Inc. is a subsidiary of Sanovas Ophthalmology, LLC.

Visit Website

Earnings History & Surprises

RTGN

Beat Rate

Last 0 quarters

Avg Surprise

+0%

EPS vs Estimate

Beats / Misses

0/0

Last 12 quarters

Latest EPS

$-0.04

Q3 2023

EPS Surprise History

Q4 22

No data

Q1 23

No data

Q2 23

No data

Q3 23

No data

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q3 2023	Sep 30, 2023	—	$-0.04	—	—
Q2 2023	Jun 30, 2023	—	$-0.02	—	—
Q1 2023	Mar 31, 2023	—	$-0.03	—	—
Q4 2022	Dec 31, 2022	—	$-0.01	—	—

Frequently Asked Questions about RTGN

What is RTGN's current stock price?

RetinalGenix Technologies Inc. (RTGN) is currently trading at $3.20 per share. The stock has moved +0.00% today.

What is the analyst price target for RTGN?

No analyst price targets are currently available for this stock.

What sector is RetinalGenix Technologies Inc. in?

RetinalGenix Technologies Inc. operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the OTC exchange.

What is RTGN's market cap?

RetinalGenix Technologies Inc. has a market capitalization of $0.06 billion, making it a small-cap company.

Does RTGN pay dividends?

No, RetinalGenix Technologies Inc. does not currently pay a dividend to shareholders.